BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36727746)

  • 21. Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
    de Carvalho LFA; Gryspeerdt F; Rashidian N; Van Hove K; Maertens L; Ribeiro S; Hoorens A; Berrevoet F
    BMC Surg; 2023 Sep; 23(1):296. PubMed ID: 37775737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.
    Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A
    Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
    McIntyre CA; Cohen NA; Goldman DA; Gonen M; Sadot E; O'Reilly EM; Varghese AM; Yu KH; Balachandran VP; Soares KC; D'Angelica MI; Drebin JA; Kingham TP; Allen PJ; Wei AC; Jarnagin WR
    J Surg Oncol; 2022 Mar; 125(3):425-436. PubMed ID: 34719035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection.
    Boone BA; Zenati MS; Rieser C; Hamad A; Al-Abbas A; Zureikat AH; Hogg ME; Neal MD; Zeh HJ
    Ann Surg Oncol; 2019 May; 26(5):1503-1511. PubMed ID: 30652227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is pancreatectomy with arterial reconstruction a safe and useful procedure for locally advanced pancreatic cancer?
    Amano H; Miura F; Toyota N; Wada K; Katoh K; Hayano K; Kadowaki S; Shibuya M; Maeno S; Eguchi T; Takada T; Asano T
    J Hepatobiliary Pancreat Surg; 2009; 16(6):850-7. PubMed ID: 19844653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    Am Surg; 2022 Dec; 88(12):2899-2906. PubMed ID: 33861651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Appleby operation for locally advanced tumour of the pancreatic body and tail--a video demonstration].
    Grützmann R; Distler M; Weitz J
    Zentralbl Chir; 2015 Apr; 140(2):151-4. PubMed ID: 25874466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
    Cecchini M; Miccio JA; Pahade J; Lacy J; Salem RR; Johnson SB; Blakaj A; Stein S; Kortmansky JS; Johung KL
    Pancreas; 2020 Aug; 49(7):904-911. PubMed ID: 32658074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
    [No Abstract]   [Full Text] [Related]  

  • 35. Feasibility and safety of distal pancreatectomy with en bloc celiac axis resection (DP-CAR) combined with neoadjuvant therapy for borderline resectable and unresectable pancreatic body/tail cancer.
    Yoshitomi H; Sakai N; Kagawa S; Takano S; Ueda A; Kato A; Furukawa K; Takayashiki T; Kuboki S; Miyzaki M; Ohtsuka M
    Langenbecks Arch Surg; 2019 Jun; 404(4):451-458. PubMed ID: 30868241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
    He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
    Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery?
    Garnier J; Robin F; Ewald J; Marchese U; Bergeat D; Boudjema K; Delpero JR; Sulpice L; Turrini O
    Ann Surg Oncol; 2021 Aug; 28(8):4625-4634. PubMed ID: 33462718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study.
    He YG; Huang XB; Li YM; Li J; Peng XH; Huang W; Tang YC; Zheng L
    World J Gastrointest Oncol; 2022 Sep; 14(9):1785-1797. PubMed ID: 36187398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgical group study.
    Yamamoto T; Satoi S; Kawai M; Motoi F; Sho M; Uemura KI; Matsumoto I; Honda G; Okada KI; Akahori T; Toyama H; Kurata M; Yanagimoto H; Yamaue H; Unno M; Kon M; Murakami Y
    Pancreatology; 2018 Jan; 18(1):106-113. PubMed ID: 29153701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
    Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.